RET

RET

RET (REarranged during Transfection) is a transmembrane receptor tyrosine kinase that is activated by a complex made up of a soluble GDNF family ligand (GFL) and a co-receptor that is glycosyl phosphatidylinositol-anchored (GFRalpha).

The enteric nervous system's development depends on RET signaling. The postnatal maintenance of dopaminergic neurons depends on RET, which also controls the development of sympathetic, parasympathetic, motor, and sensory neurons. Additionally, RET functions as a driver oncogene in a number of human cancers. In papillary thyroid, lung, colorectal, pancreatic, and breast cancers, RET has been found to fuse with a number of partner genes. Tyrosine kinase inhibitors (TKIs) for RET, particularly RET-specific inhibitors, show promising results against such cancers.

RET related products

Structure Cat No. Product Name CAS No. Product Description
V3376 AST487 (NVP- AST487) 630124-46-8 AST487 (also known as NVP- AST487) is a novel and potent inhibitor of RET kinase with anticancer activity.
V4663 BBT-594 882405-89-2 BBT-594 (also known as NVP-BBT594) is a novel, potent and selective receptor tyrosine kinase RET inhibitor used for cancer treatment.
V69553 Enbezotinib (enantiomer) (TPX-0046 (enantiomer)) 2359650-19-2
V69549 FHND5071 2761152-16-1
V3552 GSK3179106 1627856-64-7 GSK3179106 is a novel, potent, selective, and gut-restricted RET kinase inhibitorwith anIC50of 0.4 nM.
V69539 NSC194598 5358-76-9
V4830 Pralsetinib (BLU 667) 2097132-94-8 Pralsetinib (GAVRETO; BLU667; BLU-667) is a novel, highly potent, selective, FDA approved RET inhibitor with anticancer activity.
V69544 Pyrazoloadenine 2380-63-4
V69547 RET-IN-22 2918281-79-3
V69551 RET-IN-23 2479961-46-9
V69554 RET-IN-24 2583767-68-2
V69540 RET-IN-25 2965703-02-8
V79251 RET-IN-26
V69543 RET-IN-3 2414374-53-9
V51535 RET-IN-4 2436473-55-9 RET inhibitor
V69545 RET-IN-5 2725770-20-5
V69550 RET-IN-6 2715208-83-4
V69546 RET-IN-7 2763386-05-4
V2168 RETV804M kinase inhibitor 2414909-94-5 RETV804M kinase inhibitor (Compound 13) is a novel and potent inhibitor of RETV804M kinase, which is the anticipated drug-resistant mutant of RET kinase.
V4933 Selpercatinib (LOXO-292; ARRY-192) 2152628-33-4 Selpercatinib (LOXO-292; ARRY-192; Retevmo) is a potent,orallybioavailableand highly selective RET (REarrangedduringTransfection) tyrosin kinaseinhibitor with IC50of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively.
Contact Us